Figures computed from official regulatory filings — .
Ownershipinsiders 0% · institutions 7.44% · short 1.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Sienna Biopharmaceuticals, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California. On December 18, 2019, Sienna Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 16, 2019.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
19 buys16 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Azoy Alexander | Other | $551.1 | SEC | ||
| Azoy Alexander |
| AwardD (derivative) |
| n/a (No price was disclosed in the filing) |
| SEC |
| Andrews Timothy K. | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Andrews Timothy K. | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Azoy Alexander | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Lizzul Paul F. | Award | n/a (No price was disclosed in the filing) | SEC |
| Beddingfield III Frederick | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Azoy Alexander | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Beddingfield III Frederick | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Azoy Alexander | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Beddingfield III Frederick | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Azoy Alexander | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Azoy Alexander | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Beddingfield III Frederick | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Azoy Alexander | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Andrews Timothy K. | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Azoy Alexander | Award | n/a (No price was disclosed in the filing) | SEC |
| Beddingfield III Frederick | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Beddingfield III Frederick | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Andrews Timothy K. | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Lizzul Paul F. | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Lizzul Paul F. | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Lizzul Paul F. | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Andrews Timothy K. | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Beddingfield III Frederick | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |